ChronoScale Holdings Corp
CHRNNasdaq
$26.43
↑ +2.8%Jul 17 close · end-of-day
Price
1Y↑ +696.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
—
Enterprise Value
—
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$11.6M
Net Income (TTM)
-$15.7M
Free Cash Flow (TTM)
-$12.1M
Gross Margin
52.9%
Operating Margin
-134.1%
Net Margin
-135.7%
ROE
-750.7%
ROIC
—
Debt / Equity
—
Net Cash
$4.0M
Return 1Y
+608.6%
Company profile
Ekso Bionics Holdings, Inc. designs, develops, sells, rents, and rents exoskeleton products. EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury. The company has a license agreement with Lockheed Martin Corporation.
- CEO
- Steven Sherman
- Sector
- Manufacturing
- Industry
- Machinery
- Employees
- 60
- Headquarters
- California
- Website
- eksobionics.com
Management & directors
- Chen Ying CenlyChief Executive Officer
- Wong JeromeChief Financial Officer
- Jones Jason CChief Operating Officer
- Davis Scott G.CEO
Roles derived from SEC Form 4 filings.
Earnings
CHRN Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$2.1M↓ -36.6%
Diluted EPS-$2.04↑ +10.9%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $8.9M | $11.2M | $12.9M | $18.3M | $17.9M | $12.8M |
| Gross profit | $5.1M | $6.7M | $6.2M | $9.1M | $9.5M | $6.8M |
| Operating income | -$13.3M | -$13.8M | -$15.6M | -$15.1M | -$10.5M | -$13.3M |
| Net income | -$15.8M | -$9.8M | -$15.1M | -$15.2M | -$11.3M | -$11.7M |
| Diluted EPS | -$2.21 | -$0.88 | -$1.16 | -$1.10 | -$8.43 | -$4.91 |
| Operating cash flow | -$8.8M | -$11.2M | -$14.7M | -$12.1M | -$9.8M | -$11.8M |
| Free cash flow | -$8.8M | -$11.2M | -$14.9M | -$12.2M | -$9.9M | -$12.0M |
| Gross margin | 57.1% | 60.0% | 48.1% | 49.7% | 53.1% | 53.5% |
| Operating margin | -149.6% | -123.0% | -120.5% | -82.7% | -58.4% | -104.1% |
| Net margin | -178.2% | -86.8% | -116.8% | -83.1% | -63.2% | -91.4% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.0M | $4.1M | $5.1M | $3.4M | $2.1M | $4.2M | $3.1M | $2.1M |
| Gross profit | $2.6M | $2.2M | $2.7M | $1.8M | $819,000.00 | $2.5M | $1.7M | $1.1M |
| Operating income | -$2.3M | -$2.6M | -$2.2M | -$3.4M | -$4.0M | -$1.4M | -$4.5M | -$5.6M |
| Net income | -$2.4M | -$2.1M | -$3.4M | -$2.9M | -$2.7M | -$1.4M | -$4.7M | -$6.9M |
| Diluted EPS | -$1.99 | -$1.53 | -$4.71 | -$1.84 | -$1.24 | -$0.54 | -$1.29 | -$2.04 |
| Operating cash flow | -$2.7M | -$2.3M | -$1.4M | -$2.0M | -$3.4M | -$2.1M | -$4.3M | -$2.1M |
| Free cash flow | -$2.7M | -$2.3M | -$1.5M | -$2.0M | -$3.5M | -$2.1M | -$4.5M | -$2.1M |
| Gross margin | 53.3% | 53.5% | 53.3% | 53.5% | 39.8% | 60.3% | 53.2% | 50.2% |
| Operating margin | -47.2% | -63.9% | -43.8% | -101.9% | -193.2% | -33.2% | -143.6% | -262.4% |
| Net margin | -48.8% | -50.2% | -67.1% | -85.7% | -131.7% | -33.6% | -148.9% | -321.6% |
Company news
Jun 13, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-13 | Chen Ying Cenly· Chief Executive Officer | Award | 2,800,000 | $0.00 | $0.00 | filing |
| 2026-06-29 | Schaap Andrew Cordell | Award | 200,000 | $0.00 | $0.00 | filing |
| 2026-05-14 | Cummins Wes | Award | 200,000 | $0.00 | $0.00 | filing |
| 2026-05-14 | Gendel Ella | Award | 200,000 | $0.00 | $0.00 | filing |
| 2026-05-14 | Nottenburg Richard N | Award | 200,000 | $0.00 | $0.00 | filing |
| 2026-05-14 | Wong Jerome· Chief Financial Officer | Award | 40,000 | $0.00 | $0.00 | filing |
| 2026-05-14 | Davis Scott G. | Award | 109,357 | $0.00 | $0.00 | filing |
| 2026-05-14 | MILLER DOUGLAS S | Award | 200,000 | $0.00 | $0.00 | filing |
| 2026-05-14 | CLANCY WILLIAM M | Award | 200,000 | $0.00 | $0.00 | filing |
| 2026-03-16 | Jones Jason C· Chief Operating Officer | Buy | 1,308 | $11.85 | $15,499.80 | filing |
| 2026-03-16 | Wong Jerome· Chief Financial Officer | Buy | 1,308 | $11.85 | $15,499.80 | filing |
| 2026-02-19 | ASHER DANIEL | Buy | 15,540 | $12.30 | $191,162.20 | filing |
| 2026-02-19 | ASHER DANIEL | Buy | 1,200 | $9.60 | $11,520.00 | filing |
| 2026-02-13 | ASHER DANIEL | Buy | 16,100 | $8.96 | $144,273.71 | filing |
| 2026-02-13 | ASHER DANIEL | Buy | 11,092 | $9.14 | $101,413.05 | filing |
| 2026-02-12 | ASHER DANIEL | Buy | 30,124 | $9.69 | $291,841.31 | filing |
| 2026-02-12 | ASHER DANIEL | Buy | 8,908 | $9.18 | $81,814.64 | filing |
| 2026-02-11 | ASHER DANIEL | Buy | 20,611 | $9.69 | $199,770.06 | filing |
| 2026-02-10 | ASHER DANIEL | Buy | 10,200 | $9.92 | $101,224.80 | filing |
| 2026-02-09 | ASHER DANIEL | Buy | 4,800 | $9.96 | $47,820.00 | filing |
| 2026-02-06 | ASHER DANIEL | Buy | 194 | $9.86 | $1,911.91 | filing |
| 2026-01-06 | Jones Jason C· Chief Operating Officer | Sale | 1,320 | $9.25 | $12,210.00 | filing |
| 2025-12-09 | Wong Jerome· Chief Financial Officer | Sale | 1,238 | $4.70 | $5,818.60 | filing |
| 2025-12-09 | Jones Jason C· Chief Operating Officer | Sale | 270 | $4.70 | $1,269.00 | filing |
| 2025-11-10 | Davis Scott G.· CEO | Sale | 23,315 | $4.80 | $111,912.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.